BioCryst Pharmaceuticals, Inc. (BCRX) stock prices were up a promising 4.95% as of market close on April 21st, 2021, bringing the price per share up to USD$11.66. Subsequent pre-market fluctuations saw the stock price drop marginally by 1.46% to USD$11.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Rampant Successes in 2020
2020 had been a blockbuster year for BCRX, as indicated by the company’s successful foray into the U.S. market following two approvals for ORLADEYO. The company also completed the compilation of proof of concept data for BCX9930 as well as a successful phase 1 trial of BCX9250 for FOP. Further consolidating 2020 as a transformational year, the company generated more than USD$425 million in the May-December period.
Where BCRX Stands at Onset of 2021
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Building upon the successes of the previous year and their strong financial position, the company expects their success to carry on through 2021. With ORLADEYO now generating revenue in markets across the U.S., Europe, and Japan, investors are hopeful. A major milestone for the upcoming year is the significant advancement of their BCX9930 program.
The first approval for ORLADEYO came on December 3rd 2020 from the U.S. Food and Drug Administration (FDA), with the shipping of products commencing from December 16th 2020. On January 22nd, 2021, ORLADEYO received its second approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW). The approval was for both marketing and manufacturing of ORLADEYO in the treatment of patients 12 years and older. Notably, ORLADEYO is the first medication of its kind to be approved for commercialization in Japan.
Royalty Pharma Provides Capital
December 7th, 2020 saw BCRX announced the generation of USD$325 million in funding transactions. The company received an upfront USD$125 million from Royalty Pharma in exchange for royalties on direct annual net sales of ORLADEYO, with a cap of USD$550 milion. The company will also receive royalties amounting to 1% of the global net sales of BCX9930.
Additional Funding from Athyreum Capital
BCRX was also granted a USD$200 million credit option, from which it drew USD$125 million, from Athyreum Capital Management. The surplus funds will be released in two portions upon the reaching of pre-defined revenue milestones, as per BCRX’s option. This credit facility carries an interest rate of LIBOR+8.25%, with a LIBOR flow of 1.75%.
BCRX’s Financial Position
The company reported having USD$302.6 in cash, cash equivalents, restricted cash, and investments as of December 31st, 2020. This represents a growth from the USD$137.8 million reported on December 31st, 2019. BCRX anticipates its consolidated financial position securing its operations through to 2023.
Bright Outlook Expected for BCRX
With such promising developments and a huge influx of cash at their disposal, BCRX is primed to continue their stellar performance through 2021. Investors are hopeful that the company will continue to make decisions and allocate resources in ways that will consistently increase shareholder value.